| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation International HIV Controllers Study Science 330 (6010), 1551-1557, 2010 | 1109 | 2010 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 577 | 2008 |
| Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset … A Moretta, C Bottino, D Pende, G Tripodi, G Tambussi, O Viale, A Orengo, ... The journal of experimental medicine 172 (6), 1589-1598, 1990 | 499 | 1990 |
| Interleukin-2 therapy in patients with HIV infection INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee New England Journal of Medicine 361 (16), 1548-1559, 2009 | 426 | 2009 |
| The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia G Pantaleo, JF Demarest, T Schacker, M Vaccarezza, OJ Cohen, ... Proceedings of the National Academy of Sciences 94 (1), 254-258, 1997 | 359 | 1997 |
| Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors M Ripa, L Galli, A Poli, C Oltolini, V Spagnuolo, A Mastrangelo, C Muccini, ... Clinical Microbiology and Infection 27 (3), 451-457, 2021 | 356 | 2021 |
| A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. A Moretta, G Tambussi, C Bottino, G Tripodi, A Merli, E Ciccone, ... The Journal of experimental medicine 171 (3), 695-714, 1990 | 329 | 1990 |
| HIV-1 DNA predicts disease progression and post-treatment virological control JP Williams, J Hurst, W Stöhr, N Robinson, H Brown, M Fisher, S Kinloch, ... elife 3, e03821, 2014 | 320 | 2014 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 259 | 2008 |
| Short-course antiretroviral therapy in primary HIV infection SPARTAC Trial Investigators New England Journal of Medicine 368 (3), 207-217, 2013 | 242 | 2013 |
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized … Y Levy, I Sereti, G Tambussi, JP Routy, JD Lelievre, JF Delfraissy, ... Clinical infectious diseases 55 (2), 291-300, 2012 | 240 | 2012 |
| Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. C Bottino, G Tambussi, S Ferrini, E Ciccone, P Varese, MC Mingari, ... The Journal of experimental medicine 168 (2), 491-505, 1988 | 239 | 1988 |
| Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers ÁH Borges, MJ Silverberg, D Wentworth, AE Grulich, G Fätkenheuer, ... Aids 27 (9), 1433-1441, 2013 | 216 | 2013 |
| Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy GP Rizzardi, A Harari, B Capiluppi, G Tambussi, K Ellefsen, D Ciuffreda, ... The Journal of clinical investigation 109 (5), 681-688, 2002 | 212 | 2002 |
| Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions K Titanji, F Chiodi, R Bellocco, D Schepis, L Osorio, C Tassandin, ... Aids 19 (17), 1947-1955, 2005 | 204 | 2005 |
| Risk of cancers during interrupted antiretroviral therapy in the SMART study MJ Silverberg, J Neuhaus, M Bower, D Gey, A Hatzakis, K Henry, ... Aids 21 (14), 1957-1963, 2007 | 198 | 2007 |
| Immunological biomarkers predict HIV-1 viral rebound after treatment interruption J Hurst, M Hoffmann, M Pace, JP Williams, J Thornhill, E Hamlyn, ... Nature communications 6 (1), 8495, 2015 | 187 | 2015 |
| Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden S Spudich, M Gisslen, L Hagberg, E Lee, T Liegler, B Brew, D Fuchs, ... Journal of Infectious Diseases 204 (5), 753-760, 2011 | 178 | 2011 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| Antigen-driven C–C Chemokine-mediated HIV-1 Suppression by CD4+ T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele L Furci, G Scarlatti, S Burastero, G Tambussi, C Colognesi, C Quillent, ... The Journal of experimental medicine 186 (3), 455-460, 1997 | 161 | 1997 |
